Clinical trials: Endometrium Cancer, open to volunteers
Ovarian Clear Cell Carcinoma, Endometrial Cancer
TR115 in ARID1A-Mutated Advanced Solid Tumors
This is an open-label, multicenter, exploratory Phase II study to evaluate the efficacy and safety of TR115, an EZH2 inhibitor, in patients with advanced solid tumors carrying ARID1A gene mutations.
- Conditions
- Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer
- Trial name
- NCT07793318
- Testing
- TR115
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tarapeutics Science Inc.
Endometrial Cancer, Endometrial Adenocarcinoma
Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer
Clinical experience with hypo fractionated radiotherapy to date has shown that it is a safe and effective way to treat many types of cancer.
- Trial name
- HEROS (NCT07871838)
- Testing
- Hypo fractionated RT
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Triple Negative Breast Cancer, HER2-negative Breast Cancer
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
- Trial name
- NCT06999187
- Testing
- DR-0202
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Dren Bio
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
This phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and that has come back (recurrent).
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT04469764
- Testing
- Abemaciclib, Anastrozole, Letrozole
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Endometrial Cancer Stage I, Endometrial Cancer Stage II
PROfiling Based Endometrial Cancer Adjuvant Therapy
This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic…
- Trial name
- PROBEAT (NCT05179447)
- Testing
- Vaginal brachytherapy, External beam radiotherapy, Observation
- Where
- 10 sites in China
- Volunteers
- 590 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Abnormal Uterine Bleeding, Endometriosis
Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic…
- Conditions
- Abnormal Uterine Bleeding, Endometriosis, Uterine Prolapse, Uterine Cancer
- Trial name
- BARHYSTER (NCT06024109)
- Testing
- Closure of the Vaginal Cuff after Total Hysterectomy
- Where
- 2 sites in Germany, Spain
- Volunteers
- 132 people
- Sponsor
- Aesculap AG
Gynecologic Cancer, Endometrial Cancer
Mindfulness in Endometrial and Cervical Cancer
Patients with endometrial cancer who will be undergoing surgery or patients with cervical cancer who will be treated with chemoradiation will be randomized to utilize the Headspace smartphone application or not prior to their…
- Conditions
- Gynecologic Cancer, Endometrial Cancer, Cervical Cancer, Quality of Life
- Trial name
- MECCA (NCT04512144)
- Testing
- Headspace Smartphone Application
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- St. Louis University
Endometrial Cancer, Uterine Neoplasms
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer
RAINBO NSMP-ORANGE aims to investigate if adjuvant radiotherapy with oral progestin tablets is as effective as radiotherapy with chemotherapy, whilst reducing toxicity and thus improving quality of life, in patients with…
- Trial name
- NSMP-ORANGE (NCT07831902)
- Testing
- medroxyprogesterone acetate tablets OR megestrol acetate, Cisplatin, Carboplatin + Paclitaxel
- Where
- 12 sites in United Kingdom
- Volunteers
- 600 people
- Sponsor
- University College, London
HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
- Trial name
- NCT05150691
- Testing
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir
- Where
- 102 sites in United States, Australia and 4 more
- Volunteers
- 796 people
- Sponsor
- DualityBio Inc.
Advanced Endometrial Cancer
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab…
- Trial name
- NCT05112991
- Testing
- Envafolimab+Lenvatinib, Envafolimab
- Where
- 19 sites in China
- Volunteers
- 108 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Endometrial Cancer, Radiotherapy, Adjuvant
MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer
Rationale: External beam radiotherapy (EBRT) is an important cornerstone in treatment to reduce locoregional relapse in high(-intermediate) risk endometrial cancer (EC) patients.
- Trial name
- MASTEC (NCT07514325)
- Testing
- MR-guided adaptive radiotherapy (MGART) with reduced PTV margins, including 5 times 6Gy to the vaginal vault and pelvic nodal areas, 2 times a week
- Volunteers
- 61 people
- Sponsor
- Radboud University Medical Center
Endometrial Cancer, Cervical Cancer
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
- Conditions
- Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma
- Trial name
- NCT06293898
- Testing
- BL-M07D1
- Where
- 26 sites in United States
- Volunteers
- 280 people
- Sponsor
- SystImmune Inc.
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Endometrial Neoplasms, Endometrial Neoplasm Malignant
Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer
The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1/2 myometrial invasion.
- Conditions
- Endometrial Neoplasms, Endometrial Neoplasm Malignant, Endometrial Neoplasm Malignant Stage I, Carcinoma, Endometrioid
- Trial name
- NCT05945407
- Testing
- Indication-extended Fertility-sparing Therapy
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Peking University People's Hospital
Estrogen Receptor-positive, Early Stage Endometrial Cancer
Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma
This is a window of opportunity study designed to provide short duration exposure to camizestrant prior to planned curative intent surgery, with the anticipated benefit of demonstrating target engagement and suppression of ER…
- Trial name
- CARA (NCT07840443)
- Testing
- Camizestrant
- Where
- 6 sites in Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma
Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers
This study is to find out how well liquid biopsies work as a non-invasive alternative to other methods of finding cancer cells (such as a tissue biopsy) in patients with endometrial cancer.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT05049538
- Testing
- Biospecimen Collection, Liquid Biopsy, Pap Smear
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- M.D. Anderson Cancer Center
Platinum-resistant Ovarian Cancer, Testicular Cancer
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with…
- Conditions
- Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
- Trial name
- NCT06515613
- Testing
- CTIM-76
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 156 people
- Sponsor
- Context Therapeutics Inc.
Endometrial Cancer
Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4
MITO END-4 is a prospective, single arm, multicentric phase II trial aiming to assess whether Inavolisib is effective in the treatment of advanced endometrial carcinoma with pathogenic PIK3CA mutation.
- Trial name
- MITO END-4 (NCT07522697)
- Testing
- Inavolisib
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute, Naples
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Endometrial Carcinoma
Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain
This phase IV trial studies whether low dose aspirin can be used to lower inflammation and prevent endometrial cancer in postmenopausal women with changes in the endometrial tissue that are not related to thinning (non-atrophic…
- Trial name
- NCT07281547
- Testing
- Biospecimen Collection, Low-Dose Aspirin, Patient Observation
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic